Name: Latest research reports of Indegene Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Indegene Ltd.
Rating: 3
Author: Motilal Oswal

Indegene Ltd.

NSE: INDGN | BSE: 544172 | ISIN: INE065X01017 | Industry: Healthcare Services
| Turnaround Potential

666.2000 0.15 (0.02%)

NSE Nov 13, 2026 15:31 PM

New 52W High today

Volume: 1.3M

High volume today

Indegene Ltd.

02 May 2026

666.20

0.02%

Performance in line; FY27 likely to be better than FY26

Neutral: Indegene Ltd.

Target

Motilal Oswal

Indegene’s 4QFY26 revenue rose to 6.5% QoQ to INR10b (in line with our estimate), while Ex-BioPharm revenue growth stood at 5.6%.

Institutional Investors have increased holdings from 18.66% to 28.22% in Sep 2026 qtr.